

**Amendments to the Specification**

Please replace the title at page 1, line 1, with the following rewritten title:

**NOVEL USE/TREATMENT OF BONE METASTASES BY MEANS OF PTH RECEPTOR AGONISTS**

Please insert as the first paragraph the following claim to benefit of priority.

This application is a national stage entry of PCT application, PCT/US05/01139, filed January 13, 2005, which claims priority to U.S. provisional application 60/538,512, filed January 26, 2004, both of which are incorporated herein by reference.

Please replace paragraph 0057 with the following paragraph.

As used herein, "reducing bone loss" means that the cancer patient's bone density remains the same, or does not decrease as rapidly as it would without the administration of a PTH receptor agonist. Generally, it is preferable that the patient's bone density remains the same at the time that treatment is initiated and decrease only minimally thereafter during treatment. Preferably, the patient's bone density decrease is inhibited by about 85%, 90%, 95%, 99%, or more (do we want to include the possibility of enhancing bone growth, where the patient's bone density actually increases, in addition to just "reducing bone loss"? or is this not practical or desirable for the application?). When determining the rate of change or amount of change in bone density, patients may serve as their own controls, or their bone densities may be compared to statistically-derived levels, determined, for example, by clinical trials. One such trial is described by Neer, et al., *N. Engl. J. Med.* 344: 1434-41 (2001).